Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Warrant (NQ:DRMAW)

0.0249 UNCHANGED
Streaming Delayed Price Updated: 9:39 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 280
Open 0.0249
Bid (Size) 0.0175 (1)
Ask (Size) 0.0256 (30)
Prev. Close 0.0249
Today's Range 0.0249 - 0.0249
52wk Range 0.0070 - 0.0440
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Via ACCESS Newswire
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire

Performance

YTD
+68.2%
+68.2%
1 Month
+63.8%
+63.8%
3 Month
-16.4%
-16.4%
6 Month
+126.4%
+126.4%
1 Year
+47.3%
+47.3%

More News

Read More
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Via ACCESS Newswire
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Via ACCESS Newswire
Dermata to Present on BioPub on January 31, 2025
Via ACCESS Newswire
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
Via ACCESSWIRE
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Via ACCESSWIRE
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
Via ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
From Virtual Investor Conferences
Via GlobeNewswire
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
Via ACCESSWIRE
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
Via ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on April 3, 2024
Via ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on February 7, 2024
Via ACCESSWIRE
Why Dermata Therapeutics Stock Took Off After-Hours
Via Benzinga
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
Via ACCESSWIRE
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE

Frequently Asked Questions

Is Dermata Therapeutics, Inc. - Warrant publicly traded?
Yes, Dermata Therapeutics, Inc. - Warrant is publicly traded.
What exchange does Dermata Therapeutics, Inc. - Warrant trade on?
Dermata Therapeutics, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Dermata Therapeutics, Inc. - Warrant?
The ticker symbol for Dermata Therapeutics, Inc. - Warrant is DRMAW on the Nasdaq Stock Market
What is the current price of Dermata Therapeutics, Inc. - Warrant?
The current price of Dermata Therapeutics, Inc. - Warrant is 0.0249
When was Dermata Therapeutics, Inc. - Warrant last traded?
The last trade of Dermata Therapeutics, Inc. - Warrant was at 05/09/25 09:39 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.